| P2093 | author name string | Jasmine Zain | |
| | Salvia Jain | |
| P2860 | cites work | Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates | Q44813168 |
| | Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes | Q45213589 |
| | Epigenetic modifiers: basic understanding and clinical development. | Q45976173 |
| | Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin | Q46121294 |
| | Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. | Q46853686 |
| | Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). | Q46988409 |
| | Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. | Q51103802 |
| | Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. | Q54082935 |
| | Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT) | Q77486032 |
| | Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma | Q79734221 |
| | A phase II study of depsipeptide in refractory metastatic renal cell cancer | Q79960159 |
| | Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report | Q80025960 |
| | Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome | Q80538299 |
| | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 |
| | Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results | Q28300282 |
| | Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms | Q33341474 |
| | A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. | Q33345375 |
| | Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma | Q33375600 |
| | Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma | Q33386623 |
| | A subnanogram API LC/MS/MS quantitation method for depsipeptide FR901228 and its preclinical pharmacokinetics | Q33421623 |
| | Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma | Q33726989 |
| | Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group | Q33773306 |
| | Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma | Q33935031 |
| | FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity | Q34291658 |
| | FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice | Q34340614 |
| | Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma | Q34441748 |
| | FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. | Q34472558 |
| | Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336) | Q34510205 |
| | Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia | Q34659942 |
| | The Sézary syndrome: hematologic criteria | Q35622814 |
| | Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies | Q36129533 |
| | Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma | Q37253554 |
| | Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report | Q37406827 |
| | Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma | Q39981886 |
| | Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma | Q40070617 |
| | Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1. | Q40474222 |
| | A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. | Q40477758 |
| | Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma | Q40520464 |
| | T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance | Q40583269 |
| | Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins | Q40628442 |
| | Clinical trials and efficacy assessment in the therapy of cutaneous T cell lymphoma. | Q40682280 |
| | Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients | Q41612139 |
| | Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas | Q41614225 |
| | Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma | Q42942114 |
| | Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report | Q43775906 |
| | FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases | Q44123685 |
| | Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. | Q44542336 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 37-47 | |
| P577 | publication date | 2011-04-04 | |
| P1433 | published in | Journal of Blood Medicine | Q15817438 |
| P1476 | title | Romidepsin in the treatment of cutaneous T-cell lymphoma | |
| P478 | volume | 2 | |